Blood Biomarkers in Major Depression
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Major Depressive Disorder
- Sponsor
- Assistance Publique Hopitaux De Marseille
- Enrollment
- 275
- Locations
- 1
- Primary Endpoint
- describe a transcriptional signature of the Major Depressive Episode.
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
Depression is a leading cause of disability worldwide, affecting nearly 16% of the general population. Its physiopathology remains unclear. Based on gene-environment studies and epigenetic studies, a main hypothesis proposed that the major depressive episode (MDE) results from the convergence of multiple factors including biological factors such as multi-genic vulnerability, hormonal and immunological variations as well as environmental factors. As a consequence, mRNA could define a biological signature of the MDE.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Major depressive disorder at inclusion according to the DSM IV at the time of the inclusion,
- •Having a score on the scale of depression of Hamilton ( HDRS-17) \> 19 at the time of the inclusion,
- •Taken care by a grown-up psychiatric department, that the coverage(care) is realized in ambulatory or during a hospitalization
Exclusion Criteria
- •Schizophrenia
Outcomes
Primary Outcomes
describe a transcriptional signature of the Major Depressive Episode.
Time Frame: 6 months
The major aim of our study is to compare the expression level of selected genes between patient suffering from major depression and control subjects and within patients across the MDE evolution. We plan to describe a transcriptional signature of the MDE.
Secondary Outcomes
- evaluate the role played by confounding factors as genetic polymorphisms,(6 months)